Are you passionate about research in oncology? Are you a world champion in designing and executing in vivo preclinical studies? Do you want to be part of a strong global research team on an exciting journey to bring better treatments to patients? Then you might be exactly who we are looking for!
Galecto, Inc. is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of cancer and fibrosis. We have recently completed a successful IPO on Nasdaq US and raised more than $150 million in 2020 to accelerate development of its clinical pipeline and support preparations for potential EU conditional approval of GB0139 in IPF and multiple new phase II clinical trials.
Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. Our team has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme, and how both influence multiple biological pathways of these complex, often devastating, diseases. Currently, we are running four clinical trials in cancer and fibrosis.
Preferably based in UK (preferably Stevenage, London, or Edinburgh), with potential travel across the UK and EU, working closely with colleagues within Pharmacology, Medicinal Chemistry, Nonclinical, Clinical and Regulatory Affairs, you will have specific responsibility for the design, implementation, and management of all Galecto’s external in vivo studies at CROs and academic collaborators.
As the preclinical area within Galecto expands, we are looking for a highly motivated and skilled Director of In vivo Pharmacology to take an active role in driving the drug discovery projects. You will be collaborating closely with our in-house Edinburgh in vivo office/laboratories in the NINE BioQuarter in Edinburgh, UK. You will have a unique opportunity to part of driving the drug discovery process from preclinical through to the clinical phases in a dynamic and ambitious biotech team. You will report to the Head of Pharmacology.
If the above description sparks a fire inside, we hope to hear from you!
For further information, please contact our VP, Pharmacology, Rob Slack, email: rjslack@galecto.com, or our Head of People, Pernille Aasholm, email: pah@galecto.com.
Applications should be submitted no later than 1st February 2022. Please observe that there will be an on-going screening process and that the position can be filled before last application date. Please send your application by using the following link: https://galecto.bamboohr.com/jobs/view.php?id=21.
Diversity is decremental to our culture, why giving full and fair consideration to all applicants without regard to gender, religion, race, national or ethnic origin, cultural background, social group, disability, sexual orientation, gender identity, marital status age or political opinion is paramount to us.
With office locations around the world and over 15 nationalities, we’re proud to be an equal opportunity workplace with diverse perspectives and ideas. We work hard every day, but we also take the time to catch up with colleagues over a cup of coffee because our team is just as important as our science!
Find out more here.
For further information about GALECTO see www.galecto.com
Copyright © 2022 Stevenage Bioscience Catalyst
We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.